相关实验视频

Updated: May 6, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

皮下双特异抗体epcoritamab的最佳剂量方案,用于复发性或耐火性大B细胞淋巴瘤

Tommy Li¹, Leonid Gibiansky², Apurvasena Parikh³

¹Genmab, Plainsboro, New Jersey, USA.

Clinical pharmacology and therapeutics

|February 12, 2025

概括

双特异性抗体epcoritamab有效治疗复发性或耐火性淋巴瘤. 高剂量与更好的反应率和存活率相关,经批准的治疗方案显示可管理的安全性和持续的疗效.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药理学药理学是指药理学的学科.

背景情况:

埃普科里塔马布是一种经批准的CD3xCD20双特异性抗体,用于复发性或耐火性淋巴瘤.
它激活T细胞以消除表达CD20的B细胞.

研究的目的:

评估epcoritamab在复发或耐火性大B细胞淋巴瘤患者中的暴露-疗效和暴露-安全关系.
为了支持已批准的单剂epcoritamab剂量方案.

主要方法:

从1/2期EPCORE® NHL-1试验扩展和EPCORE NHL-3试验的数据分析.
进行了暴露有效性和暴露安全性分析.

主要成果:

较高的epcoritamab暴露与改善的整体响应率,完全响应率,无进展生存率和整体生存率有关.
在48毫克或更高的剂量下,疗效似乎停滞不前.
经批准的剂量方案证明了可管理的安全性,没有发现暴露安全问题.
升级剂量在减轻细胞因子释放综合征风险方面是有效的.

结论:

已批准的单剂epcoritamab剂量方案 (0.16/0.8/48 mg) 得到了暴露有效性和暴露安全性数据的支持.
剂量计划,包括逐步增加剂量,对于治疗复发性或耐火性大B细胞淋巴瘤是有效和安全的.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.